title: Effects of ciprofibrate on LDL metabolism in man.
abstract: This study examined the effects of ciprofibrate therapy (100 mg/day) on plasma lipids, lipoproteins and low density lipoprotein (LDL) kinetic heterogeneity in moderately hypercholesterolaemic subjects. The drug lowered plasma triglyceride and cholesterol by 41% and 17%, respectively. Very low density lipoprotein (VLDL) cholesterol fell by 38%, LDL cholesterol fell by 22%, while the content of the lipid in high density lipoprotein (HDL) increased by 11%. LDL structural and metabolic heterogeneity were assessed before and during therapy in eight subjects. Density gradient centrifugation was used to fractionate LDL into three species. LDL-I, the least dense, was not affected by therapy whereas LDL-II and LDL-III were decreased by 28% (P < 0.01) and 31% (N.S.). Baseline turnover studies revealed that LDL catabolism was subnormal and this was the cause of the raised cholesterol in these subjects. Ciprofibrate therapy increased the apoLDL fractional catabolic rate (FCR) by 19%, principally by inducing a 38% enhancement (P < 0.03) in apoLDL removal by the receptor pathway. ApoLDL kinetics exhibited metabolic heterogeneity both before and during drug therapy. Analysis of plasma decay curves for the LDL tracer and urinary excretion data indicated that the lipoprotein comprised two metabolically distinct species, one with an FCR of about 0.50 pools/day (Pool A), the other with an FCR of about 0.18 pools/day (Pool B). Drug therapy decreased synthesis of and hence reduced the plasma mass of apoLDL in the slow metabolised pool B. This perturbation in synthesis was linked to the change in plasma triglyceride concentration. The resultant reduced proportion of pool B vs. pool A material accounted for the observed promotion of LDL receptor-mediated clearance. Ciprofibrate, therefore, produced beneficial changes in the plasma levels of VLDL, LDL and HDL and in the metabolism of LDL.
authors.affiliation: Institute of Biochemistry, Glasgow Royal Infirmary, UK.
authors.forename: A
authors.initials: A
authors.lastname: Gaw
authors.forename: C J
authors.initials: CJ
authors.lastname: Packard
authors.forename: M J
authors.initials: MJ
authors.lastname: Caslake
authors.forename: B A
authors.initials: BA
authors.lastname: Griffin
authors.forename: G M
authors.initials: GM
authors.lastname: Lindsay
authors.forename: J
authors.initials: J
authors.lastname: Thomson
authors.forename: B D
authors.initials: BD
authors.lastname: Vallance
authors.forename: D
authors.initials: D
authors.lastname: Wosornu
authors.forename: J
authors.initials: J
authors.lastname: Shepherd
mesh_terms: D000328:Adult; D000368:Aged; D001053:Apolipoproteins / Q000378:metabolism; D002994:Clofibrate / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000188:drug therapy; D008055:Lipids / Q000097:blood; D008077:Lipoproteins, LDL / Q000378:metabolism*; D008297:Male; D008875:Middle Aged
chemical_list: D001053:Apolipoproteins; D008055:Lipids; D008077:Lipoproteins, LDL; C010681:apolipoprotein LDL, human; D002994:Clofibrate